The journal retracts the article titled “Repurposing Diltiazem for Its Neuroprotective Anti-Dementia Role against Intra-Cerebroventricular Streptozotocin-Induced Sporadic Alzheimer’s Disease-Type Rat Model” [1], cited above.
Following publication, concerns were brought to the attention of the Editorial Office regarding the integrity of figures presented in this article [1].
In accordance with the journal’s standard procedures, the Editorial Office and Editorial Board conducted an investigation, which identified indications of inappropriate image editing and duplication in Figure 7. Although the authors cooperated with the investigation, the explanations and supporting materials provided were not deemed sufficient by the Editorial Board to resolve the identified concerns. As a result, the Editorial Board has lost confidence in the reliability of the findings and has decided to retract this publication [1], in line with MDPI’s retraction policy.
This retraction was approved by the Editor-in Chief of the journal Life.
The authors have been informed of this retraction and have indicated their agreement with this decision.
Reference
- Alluri, R.; Kilari, E.K.; Pasala, P.K.; Kopalli, S.R.; Koppula, S. RETRACTED: Repurposing Diltiazem for Its Neuroprotective Anti-Dementia Role against Intra-Cerebroventricular Streptozotocin-Induced Sporadic Alzheimer’s Disease-Type Rat Model. Life 2023, 13, 1688. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.